Clinical Trials Browser

Phase 1/2 × Lymphoma × eliglustat × Clear all

NCT07138547 2026-01-02

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma

Phase 1/2 Recruiting

Lymphoma